Form 4: Denali Therapeutics Director Jennifer E. Cook Sells Shares Under 10b5-1 Trading Plan

Director Jennifer E. Cook sold 1,458 shares of Denali Therapeutics Inc. (DNLI) on June 6, 2024, at a price of $21.73 per share, according to a Form 4 filing with the SEC.

Summary

• On June 6, 2024, Jennifer E. Cook, a director of Denali Therapeutics Inc., sold 1,458 shares of common stock.
• The sale was executed at a price of $21.73 per share.
• The transaction was conducted under a pre-arranged Rule 10b5-1 trading plan adopted on March 7, 2024.
• Following the transaction, Cook directly owns 20,038 shares of Denali Therapeutics, including 5,967 unvested Restricted Stock Units (RSUs).

Sentiment

Score: 5

Explanation: The sentiment is neutral. It's a routine transaction under a pre-existing trading plan, so it doesn't necessarily indicate a positive or negative outlook.

Industry Context

Sales by company insiders are routinely monitored by investors. While not inherently negative, significant or frequent sales can sometimes signal a lack of confidence in the company's near-term prospects, or simply reflect personal financial planning.

Stakeholder Impact

• The sale of shares by a director could have a minor negative impact on shareholder sentiment, although the existence of a 10b5-1 plan mitigates this concern.

Key Dates